DelveInsight’s ‘Non-Small Cell Lung Cancer – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key Highlights from report are:
Request Sample Report @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-epidemiology-forecast
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.
NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC.
Patients of NSCLC with the resectable disease may be cured by surgery or surgery followed by chemotherapy. Local control can be achieved by radiation therapy in a large number of patients with unresectable disease. On the other hand, patients with the locally advanced unresectable disease may achieve long-term survival with radiation therapy combined with chemotherapy and the patients with advanced metastatic disease may achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and other supportive measures.
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Table of contents:
1. Key Insights2. Executive Summary of NSCLC3. NSCLC: Patient Overview at a Glance3.1. Total Patient Share (%) Distribution of NSCLC in 2017: By Country3.2. Total Patient Share (%) Distribution of NSCLC in 2030: By Country3.3. Total Patient Share (%) Distribution of NSCLC in 2017: By Mutations/ biomarkers3.4. Total Patient Share (%) Distribution of NSCLC in 2030: By Mutations/ biomarkers4. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview4.1. Introduction4.1.1. Cellular Classification of NSCLC4.1.2. Signs and Symptoms of NSCLC4.1.3. Risk Factors of Lung Cancer4.1.4. Causes of NSCLC4.1.5. Disease Biology: NSCLC5. Diagnosis of NSCLC5.1. Diagnostic Algorithm for NSCLC5.2. Stages of NSCLC5.3. Staging System6. Epidemiology and Patient Population6.1. Epidemiology Key Findings6.2. Assumptions and Rationale: 7MM6.3. Epidemiology Scenario: 7MM6.3.1. Total Incident cases of NSCLC patients in the 7MM6.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM6.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM6.4. The United States Epidemiology6.4.1. Total Incident cases of NSCLC patients in the United States6.4.2. Total Incident cases of NSCLC patients by Histology in the United States6.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States6.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States7. EU-5 Epidemiology7.1. Germany7.1.1. Total Incident cases of NSCLC patients in Germany7.1.2. Total Incident cases of NSCLC patients by Histology in Germany7.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany7.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany7.2. France7.2.1. Total Incident cases of NSCLC patients in France7.2.2. Total Incident cases of NSCLC patients by Histology in France7.2.3. Total Diagnosed cases of NSCLC patients by Stages in France7.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France7.3. Italy7.3.1. Total Incident cases of NSCLC patients in Italy7.3.2. Total Incident cases of NSCLC patients by Histology in Italy7.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy7.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy7.4. Spain7.4.1. Total Incident cases of NSCLC patients in Spain7.4.2. Total Incident cases of NSCLC patients by Histology in Spain7.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain7.5. The United Kingdom7.5.1. Total Incident cases of NSCLC patients in the United Kingdom7.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom7.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom7.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom8. Japan Epidemiology8.1. Japan8.1.1. Total Incident cases of NSCLC patients in Japan8.1.2. Total Incident cases of NSCLC patients by Histology in Japan8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan9. Appendix9.1. Bibliography9.2. Report Methodology10. DelveInsight Capabilities11. Disclaimer12. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/